Coeliac disease is an autoimmune condition triggered by gluten, leading to gut inflammation and nutrient malabsorption. Current blood tests, primarily measuring antibodies, often fail to clearly indicate the extent of ongoing inflammation or intestinal damage despite patient adherence to a gluten-free diet.
A study investigated whether blood proteins could serve as biomarkers for disease activity. Researchers analyzed blood and tissue samples from 264 individuals with coeliac disease, collected before and after a year on a gluten-free diet, alongside samples from healthy individuals. Proteomic analysis identified 24 proteins associated with coeliac disease, with nine particularly linked to intestinal damage. Untreated individuals exhibited higher levels of inflammatory proteins compared to healthy controls, while those on a gluten-free diet still showed elevated levels of some proteins. Current monitoring relies heavily on serology, which can be misleading after treatment initiation. The identified biomarkers hold potential to provide a more detailed and accurate picture of disease progression, complementing existing methods. Further research and selection of key proteins are needed before clinical implementation.